Literature DB >> 2870754

Short-term outcome in trial entrants and trial eligible patients.

J F MacMillan, T J Crow, A L Johnson, E C Johnstone.   

Abstract

Of 253 patients from nine medical centres identified with first episodes of schizophrenic illness, 17 did not achieve discharge during the period of trial recruitment. 120 entered a randomised controlled trial of neuroleptic medication and were followed-up, as were 116 who were eligible for the trial but did not enter it. Overall, 60% of the sample had relapsed within two years of discharge; age, sex, ethnic origin, duration of admission, social withdrawal before admission, and type of onset of illness were not significantly related to relapse. Relapse rates were lower on active trial or standard medication than placebo, but however assessed, outcome at this early stage was poor for many patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870754     DOI: 10.1192/bjp.148.2.128

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  10 in total

Review 1.  Antipsychotic medication for elderly people with schizophrenia.

Authors:  R G Marriott; W Neil; S Waddingham
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 2.  Outcomes for patients with the same disease treated inside and outside of randomized trials: a systematic review and meta-analysis.

Authors:  Natasha Fernandes; Dianne Bryant; Lauren Griffith; Mohamed El-Rabbany; Nisha M Fernandes; Crystal Kean; Jacquelyn Marsh; Siddhi Mathur; Rebecca Moyer; Clare J Reade; John J Riva; Lyndsay Somerville; Neera Bhatnagar
Journal:  CMAJ       Date:  2014-09-29       Impact factor: 8.262

3.  Treatment resistance in schizophrenia.

Authors:  E C Johnstone; R Sandler
Journal:  BMJ       Date:  1996-02-10

4.  A controlled trial of a counselling intervention for caregivers of relatives with schizophrenia.

Authors:  G I Szmukler; H Herrman; S Colusa; A Benson; S Bloch
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1996-06       Impact factor: 4.328

5.  The costs of schizophrenia in Puerto Rico.

Authors:  M Rubio-Stipec; B Stipec; G Canino
Journal:  J Ment Health Adm       Date:  1994

Review 6.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  Long-term follow-up of young Afro-Caribbean Britons and white Britons with a first admission diagnosis of schizophrenia.

Authors:  D McGovern; P Hemmings; R Cope; A Lowerson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1994-02       Impact factor: 4.328

8.  On the selection of mice for haloperidol response and non-response.

Authors:  R Hitzemann; K Dains; C M Bier-Langing; N R Zahniser
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

9.  Course of patients diagnosed as having schizophrenia during first episode occurring under age 18 years.

Authors:  M Schmidt; B Blanz; A Dippe; T Koppe; B Lay
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

Review 10.  Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.

Authors:  Jataveda Mahapatra; Seema N Quraishi; Anthony David; Stephanie Sampson; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.